Neon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.
The company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard International, Arrowmark Partners, Hillhouse Capital and Casdin Capital. The IPO will be led by Morgan Stanley, BofA Merrill Lynch and Mizuho Securities.
Neon is developing a pipeline of personalized neoantigen vaccines and autologous T cell therapies, with an initial focus on melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. The company has collaboration and licensing agreements in place with Vedantra Pharmaceuticals, Apexigen, CRISPR Therapeutics, Bristol-Myers Squibb, Merck, the Netherlands Cancer Institute, the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital.
Source: Neon Therapeutics
In May 2018, Neon announced that it had treated its first patient in a Phase I clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck’s Keytruda (anti PD-1 therapy) and a chemotherapy regimen of pemetrexed and carboplatin in patients with untreated or advanced metastatic nonsquamous NSCLC. The trial is being conducted in collaboration with Merck. In addition to evaluating the safety, tolerability and preliminary efficacy of the combination therapy, the trial will assess neoantigen-specific immune responses in peripheral blood and tumor tissue, and other markers of immune response.
Treating our first patient in this clinical study marks an important milestone for Neon. We see a strong mechanistic rationale to explore the combination and sequence of a personal neoantigen cancer vaccine, anti-PD-1 therapy and chemotherapy. These data will help us understand the potential of NEO-PV-01 to improve durability and response rates of patients treated in combination with existing immuno-oncology drugs.
– Richard Gaynor, M.D., president of research and development at Neon Therapeutics.
6 Ways to Unwind This Holiday Season
It’s Never Too Soon to Start Estate Planning
Fiduciary and Best Interest Are Not Synonyms
7 Ways to Avoid Arguments During the Holiday Season
The Biggest Risk for Business Owners
A New Wrinkle in the U.S. — China Trade Dispute
Want To Make An Impact? Lead With Humble Pie
How to Go One Step Further with Your 2019 Strategic Plan
Can Verizon Overcome the Acquisition of Aol and Yahoo – That Never Made Sense
What Makes a Great Whitepaper?
Development23 hours ago
Building an RIA Firm for Maximum Value from an Investment Banker’s Perspective
Development23 hours ago
Good? Fast? or Cheap? What Sort of Advice Is It Going to Be?
Financial Podcasts23 hours ago
MarketCounsel Summit Series: The Most Important Data Questions Advisors Are Not Asking—with George Svagera
Financial Podcasts2 days ago
MarketCounsel Summit Series: Turn Fearful Clients into Fearless Investors with Aaron Klein
Research2 days ago
What Brexit and the Ongoing Problems in the European Union Mean For Investors
Building Smarter Portfolios2 days ago
Merger Arbitration Strategies and Protection
Advisor3 days ago
How to Budget for the Holidays
Social Selling3 days ago
As a Salesman I Taught Myself to Market … and You Should Too!